文献速递功能神经外科

接受神经外科手术治疗的三叉神经痛患者阿片类药物使用模式

Patterns of opioid use in patients with trigeminal neuralgia undergoing neurosurgery.
PubMed 文献 · J Neurosurg · 2019-01-11

这项回顾性研究纳入309例面部疼痛患者,20%在初诊时使用阿片类药物,其中55%与卡马西平/奥卡西平联用。神经外科干预后长期随访阿片使用降至8%(p<0.01,Fisher精确检验,n=154),三叉神经痛1型患者降至5%(p<0.05),而非1型患者未见下降;非手术组未见统计学显著下降(n=81)。

要点

  • 初诊时20%面部疼痛患者使用阿片类药物,55%与卡马西平/奥卡西平联用。
  • 神经外科干预后长期随访阿片使用降至8%(p<0.01,Fisher精确检验,n=154)。
  • 三叉神经痛1型患者术后阿片使用降至5%(p<0.05),非1型患者未见下降。

核心结论

  • 尽管阿片类药物滥用潜力高,其在面部疼痛患者中仍普遍使用,多作为抗癫痫药物的辅助用药。
  • 作者认为,三叉神经痛1型患者遏制阿片使用的机会包括更早的神经外科干预。

研究设计与样本

  • 这是一项由单一神经外科医生诊治面部疼痛患者的回顾性研究。
  • 研究队列共309例患者,其中Burchiel 1型三叉神经痛占70%,2型占18%,非典型面痛占6%,多发性硬化相关三叉神经痛占6%。
  • 所有患者完成疼痛药物、合并症、既往面部疼痛干预及Penn面部疼痛量表调查;接受神经外科干预的患者在术后1个月门诊随访时完成调查,并在干预后1至6年间通过标准化脚本进行电话访谈。
  • 采用单因素和多因素逻辑回归预测阿片类药物使用。

主要发现

  • 初诊时20%患者使用阿片类药物,其中55%同时使用卡马西平/奥卡西平,84%同时使用至少一种抗癫痫药物。
  • 基线阿片使用的预测因素包括面部疼痛诊断(非1型三叉神经痛的OR 2.5,p=0.01)和面部疼痛最严重程度(每增加1单位,OR 1.4,p=0.005)。
  • 神经外科干预后长期随访阿片使用降至8%(p<0.01,Fisher精确检验,n=154)。
  • 长期随访阿片使用的预测因素包括诊断(非1型三叉神经痛的OR 4.7,p=0.002)和干预后最严重疼痛减轻程度(每减少1单位,OR 0.8,p<10^-3)。
  • 亚组分析显示,1型三叉神经痛患者长期随访阿片使用降至5%(p<0.05,Fisher精确检验),而非1型面部疼痛患者未见下降;非手术组长期随访阿片使用未见统计学显著下降(n=81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: First-line treatment for trigeminal neuralgia (TN) is pharmacological management using antiepileptic drugs (AEDs), e.g., carbamazepine (CBZ) and oxcarbazepine (OCBZ). Surgical intervention has been shown to be an effective and durable treatment for TN that is refractory to medical therapy. Despite the lack of evidence for efficacy in patients with TN, the authors hypothesized that patients with neuropathic facial pain are prescribed opioids at high rates, and that neurosurgical intervention may lead to a reduction in opioid use. METHODS: This is a retrospective study of patients with facial pain seen by a single neurosurgeon. All patients completed a survey on pain medications, medical comorbidities, prior interventions for facial pain, and a validated pain outcome tool (the Penn Facial Pain Scale). Patients subsequently undergoing neurosurgical intervention completed a survey at the 1-month follow-up in the office, in addition to telephone interviews using a standardized script between 1 and 6 years after intervention. Univariate and multivariate logistic regression were used to predict opioid use. RESULTS: The study cohort consisted of 309 patients (70% Burchiel type 1 TN [TN1], 18% Burchiel type 2 [TN2], 6% atypical facial pain [AFP], and 6% TN secondary to multiple sclerosis [TN-MS]). At initial presentation, 20% of patients were taking opioids. Of these patients, 55% were receiving concurrent opioid therapy with CBZ/OCBZ, and 84% were receiving concurrent therapy with at least one type of AED. Facial pain diagnosis (for diagnoses other than TN1, odds ratio [OR] 2.5, p = 0.01) and facial pain intensity at its worst (for each unit increase, OR 1.4, p = 0.005) were predictors of opioid use at baseline. Neurosurgical intervention led to a reduction in opioid use to 8% at long-term follow-up (p < 0.01, Fisher's exact test; n = 154). Diagnosis (for diagnoses other than TN1, OR 4.7, p = 0.002) and postintervention reduction in pain at its worst (for each unit reduction, OR 0.8, p < 10-3) were predictors of opioid use at long-term follow-up. On subgroup analysis, patients with TN1 demonstrated a decrease in opioid use to 5% at long-term follow-up (p < 0.05, Fisher's exact test), whereas patients with non-TN1 facial pain did not. In the nonsurgical group, there was no statistically significant decrease in opioid use at long-term follow-up (n = 81). CONCLUSIONS: In spite of its high potential for abuse, opioid use, mostly as an adjunct to AEDs, is prevalent in patients with facial pain. Opportunities to curb opioid use in TN1 include earlier neurosurgical intervention.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yang AI, McShane BJ, Hitti FL, et al. Patterns of opioid use in patients with trigeminal neuralgia undergoing neurosurgery. J Neurosurg. 2019. PMID: 30641832. doi:10.3171/2018.8.JNS1893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。